Abstract: Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

Abstract: The present disclosure provides matched gut and peripheral biomarkers to assess, identify and improve therapeutic measures for IBD, in particular ulcerative colitis and Crohn's disease.

Abstract: Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

Abstract: Methods and kits are provided for the assessment of the suitability of and/or effectiveness of a target therapy for a TNF mediated-related disorder, such as ulcerative colitis, in a subject, which methods and kits evaluate the presence, absence, and/or magnitude of expression of two or more genes up or down regulated in association with anti-TNF responders in inflammatory gastrointestinal disorders, such as ulcerative colitis, with at least two genes including BCL6 (Genbank Acc. No. AW264036; SEQ ID NO:118) and tx82a04.x1 (Genbank Acc. No. AI689210; SEQ ID NO:123), optionally further comprising at least one to three of C5AR1 ((Genbank Acc. No.NM001736; SEQ ID NO: 119), FOLR1 ((Genbank Acc. No. U81501; SEQ ID NO: 142) and OSM (Genbank Acc. No. A1079327; SEQ ID NO: 173), optionally further comprising at least one of the listed genes presented in FIG. 7 with a therapeutic response to at least one anti-TNF? agents (e.g.

Abstract: Tools for diagnosis and management of patients suspected of having or having been previously diagnosed with systemic sclerosis are based on the determination one or more of the markers described herein, specifically, the markers having the amino acid sequence of SEQ ID NOS: 1-62 and 66-76 in a sample from the subject. Specific marker ratios and subsets of markers and ratios identify a patient and further subclassify the patient. The information may be used prospectively to study the response of subclassified patients to existing or novel therapeutic strategies.

Abstract: Methods and kits for the assessment of the suitability of and/or effectiveness of a target therapy for a TNF mediated-related disorder, such as ulcerative colitis, in a subject, which methods and kits evaluate the presence, absence, and/or magnitude of expression of two or more genes up or down regulated in association with anti-TNF responders in inflammatory gastrointestinal disorders, such as ulcerative colitis

Abstract: A method for assessment of the suitability of a target therapy for a gastrointestinal-related disorder, such as ulcerative colitis, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 20- or 5-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to starting a patient on such therapies.

Abstract: A method for assessment of the suitability of a target therapy for a gastrointestinal-related disorder, such as ulcerative colitis, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 19- or 5-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to starting a patient on such therapies.